Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genasense chronic leukemia NDA gets rolling

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genta has initiated a rolling NDA for use of Genasense (oblimersen) in combination with fludarabine and cyclophosphamide in fludarabine-experienced chronic lymphocytic leukemia patients, the firm says June 30. Genta expects to complete the submission within six months. The company previously indicated it would initiate a confirmatory CLL study for accelerated approval before year-end (1Pharmaceutical Approvals Monthly June 2005, p. 3); the company says it "plans to discuss the design of that study with FDA." The CLL NDA will include a Phase I/II study of Genasense alone in relapsed/refractory CLL and a Phase III study of Genasense in combination with the flu/cy regimen versus fly/cy alone. The latter study showed a significant benefit for complete response, but Genta said overall survival "is too early to analyze"...

You may also be interested in...

Genta Genasense Confirmatory Chronic Leukemia Trial To Begin By Year End

Genta plans to launch a confirmatory trial of Genasense (oblimersen sodium) in chronic lymphocytic leukemia (CLL) before the end of 2005, the firm says.

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts